In­tas to pay €42M up­front in Hen­lius deal; Kymera gets $40M mile­stone; Plu­vic­to no longer in short sup­ply

Plus, news from Vi­core, El­e­vate Bio, Monte Rosa Ther­a­peu­tics and An­gi­tia:

In­tas, Hen­lius ink an­oth­er deal: In­tas said Fri­day it plans to pay €42 mil­lion up­front to li­cense Shang­hai Hen­lius Biotech’s an­ti-PD-1 mon­o­clon­al an­ti­body in Eu­rope and In­dia for spe­cif­ic in­di­ca­tions. The terms al­so in­clude up to €43 mil­lion in reg­u­la­to­ry mile­stones and up to €100 mil­lion in sales mile­stones, plus roy­al­ties. The com­pa­nies ex­pect ser­plulimab to gain ap­proval in small cell lung can­cer in Eu­rope in the first half of next year. The com­pa­nies are al­ready en­gaged in sev­er­al agree­ments, in­clud­ing one set up in 2018 be­tween Hen­lius and Ac­cord Health­care, an In­tas sub­sidiary. — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER